Search Results 201-210 of 12276 for fibrosis quistica

  1. Teng Moua, M.D. - Mayo Clinic Faculty Profiles

    Mechanisms of progression in lung fibrosis. Dr. Moua studies the baseline characteristics and environmental factors that lead to the clinical and radiological ...

  2. https://www.mayoclinic.org/spanish_condition_consolidated_concepts.xml

  3. A Study of Normal Subsynovial Connective Tissue and Carpal Tunnel Syndrome - Mayo Clinic

    The purpose of this study is to collect normal tissue as the control for a study looking at the role of synovial fibrosis in the development of carpal tunnel ...

  4. Programs - Biliary Epigenetics and Regenerative Medicine: Robert C. Huebert

    Biliary fibrosis is the process of periportal scarring within the liver that is caused by diseased bile ducts. It often progresses to end-stage liver ...

  5. Study To Evaluate The Safety And Effectiveness Of BMS-986036 In Adults With Nonalcoholic Steatophepatitis (NASH) And Stage 3 Liver Fibrosis - Mayo Clinic

    Study To Evaluate The Safety And Effectiveness Of BMS-986036 In Adults With Nonalcoholic Steatophepatitis (NASH) And Stage 3 Liver Fibrosis · Share · Facebook ...

  6. A Study of a Computer-Aided Analysis Tool for the Assessment of Pulmonary Fibrosis Treatment - Mayo Clinic

    A Study of a Computer-Aided Analysis Tool for the Assessment of Pulmonary Fibrosis Treatment ... fibrosis. Computer-Aided Lung Informatics for Pathology ...

  7. Magnetic Resonance Elastography (MRE) - Mayo Clinic

    Vivien Williams: But to make sure her liver's not becoming stiff from fibrosis, which can lead to irreversible cirrhosis, Vicky's had a liver biopsy. Vicky ...

  8. Tezacaftor/ivacaftor and ivacaftor (oral route) - Side effects & dosage - Mayo Clinic

    Tezacaftor/ivacaftor and ivacaftor combination is used to treat cystic fibrosis (CF) in patients 6 years of age and older. It is only used for patients who ...

  9. Anti-fibrotic therapy in the treatment of IPF: Ongoing concerns and current practices - Mayo Clinic

    Pirfenidone and nintedanib are approved for treatment of idiopathic pulmonary fibrosis (IPF), but questions remain regarding indications and timing of ...

  10. Open-Label Study Of The Long Term Safety Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    Clinical Trials · Open-Label Study Of The Long Term Safety Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (IPF) · More about research at Mayo ...